Abstract, published in Epilepsy Research
Stiripentol is an orphan drug successfully used in combination with valproate (Depakote®) and clobazam (Onfi®) in the treatment of Dravet syndrome. Perampanel has also been added by experts. In this study, we investigated the influence of stiripentol on perampanel serum levels by using the doses and corresponding perampanel serum levels of 10 patients. The impact of stiripentol on the perampanel serum levels was significant, with perampanel serum levels increasing linearly with the stiripentol doses.
Researchers conclude that dose adjustments of stiripentol and perampanel when administered together, should be done carefully to avoid side effects or even severe intoxication. Hence, perampanel serum level monitoring seems advisable.